Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at Cantor’s 2026 Global Healthcare Conference, scheduled for Sept. 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., will present on Sept. 10 from 3:55-4:25 p.m. ET. A live webcast and replay will be available through the Investors section of the Tonix website, as noted in the press release.
This conference appearance comes at a pivotal time for Tonix, which recently received approval for TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) as the first new treatment for fibromyalgia in over 15 years. The company is now focused on maximizing the commercial potential of TONMYA while advancing its pipeline. According to the announcement, Tonix is conducting Phase 2 clinical trials to evaluate TONMYA in major depressive disorder and acute stress disorder, aiming to expand its indications beyond fibromyalgia.
The company’s CNS portfolio also includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder. In addition, Tonix is progressing its immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection. These pipeline assets underscore Tonix’s commitment to addressing unmet medical needs in both CNS and immunology.
The Cantor conference provides a platform for Tonix to engage with investors and industry stakeholders, potentially increasing visibility and supporting its strategic initiatives. As the company transitions to a commercial-stage entity with TONMYA, its ability to effectively communicate its value proposition is critical. The fireside chat offers an opportunity for Lederman to discuss recent developments, clinical progress, and future plans.
Tonix’s participation in this high-profile healthcare conference is likely to draw attention from analysts and investors tracking its progress. With TONMYA’s approval, the company is entering a new phase, and its performance at the conference could influence market perceptions. The one-on-one meetings also allow for in-depth discussions with potential partners or investors, which could be instrumental in supporting ongoing research and commercialization efforts.
The live webcast and replay availability ensure that stakeholders who cannot attend the conference in person can still access the presentation, demonstrating Tonix’s commitment to transparency and shareholder communication. This event is part of a broader strategy to build momentum for TONMYA and the rest of the pipeline, as the company seeks to establish itself as a leader in CNS and immunology treatments.
